Voyager Therapeutics (VYGR) EBITDA (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of EBITDA data on file, last reported at -$30.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 12.75% year-over-year to -$30.3 million; the trailing twelve-month figure through Mar 2026 stood at -$127.4 million (down 25.17% YoY), and the FY2025 full-year result was -$131.8 million, down 58.3% from the prior year.
• EBITDA eased to -$30.3 million in Q1 2026, from -$29.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $122.9 million in Q1 2023 to a low of -$38.3 million in Q4 2024.
• A 5-year average of -$10.2 million and a median of -$24.6 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 530.78% in 2022 and soared 675.57% in 2023, its largest moves.
• Tracing VYGR's EBITDA over 5 years: stood at -$24.6 million in 2022, then soared by 320.1% to $54.1 million in 2023, then tumbled by 170.84% to -$38.3 million in 2024, then advanced by 21.85% to -$29.9 million in 2025, then decreased by 1.13% to -$30.3 million in 2026.
• Business Quant data shows VYGR's EBITDA at -$30.3 million in Q1 2026, -$29.9 million in Q4 2025, and -$30.6 million in Q3 2025.